NHI.no
Annonse
Informasjon

Opioidabstinens

Når opioidene ikke lenger inntas, får kroppen en abstinensreaksjon som preges av uro, indre spenninger, hjertebank, løs mage.

Symptomer på begynnende opiatabstinens er blant annet uro, tristhet og hodepine.

Sist oppdatert:

27. juli 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Opiatabstinens . Referanselisten for dette dokumentet vises nedenfor

  1. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020;395(10241):1938-1948. PubMed
  2. Kosten TR, Baxter LE. Effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict 2019; 28: 55–62. PMID: 30701615 PubMed
  3. Amundsen EJ. Narkotikautløste dødsfall i 2021. Folkehelseinstituttet, sist oppdatert 09.06.2022. www.fhi.no
  4. Shaygani S, Waal H. Behandling av opioid abstinens. Tidsskr Nor Legeforen 2009; 129: 114-5. Tidsskrift for Den norske legeforening
  5. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD005031. DOI: 10.1002/14651858.CD005031.pub4. The Cochrane Library
  6. Gowing L, Farrell M, Ali R, White JM. Alpha2‐adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2016, Issue 5. The Cochrane Library
  7. Gowing L, Ali R, White JM. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database of Systematic Reviews 2017, Issue 5. The Cochrane Library
  8. Dunn KE, Tompkins A, Bigelow GE, et al. Efficacy of tramadol extended release for opioid withdrawal. A randomized clinial trial. JAMA Psychiatry 2017. doi:10.1001/jamapsychiatry.2017.1838 DOI
  9. Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database of Systematic Reviews 2017, Issue 2. The Cochrane Library
  10. Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD003409. DOI: 10.1002/14651858.CD003409.pub4. DOI
  11. Watts BV, Gottlieb DJ, Riblet NB, et al. Association of Medication Treatment for Opioid Use Disorder With Suicide Mortality. Am J Psychiatry 2022; 179: 298-304. pmid:35360916 PubMed
  12. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD011117. DOI: 10.1002/14651858.CD011117.pub2 DOI
  13. Gowing L, Ali R, White JM. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD002022. DOI: 10.1002/14651858.CD002022.pub3. DOI
  14. National Institute of Health and Clinical Excellence. NICE clinical guideline 52.. Drug misuse: opioid detoxification. National Institute of Health and Clinical Excellence 2007.
  15. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD004580. DOI: 10.1002/14651858.CD004580.pub2. DOI
  16. Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc 2019; 94: 2072–86. PMID: 31543255 PubMed
  17. Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet 2019; 393: 1760–72. PMID: 30878228 PubMed
Annonse
Annonse